Cybin Jumps 8% on Wall Street Cheerleading, but Can a Pre-Revenue Psychedelic Biotech Justify a $38 Price Target?

Shares shifted as Cybin Inc. — now operating as Helus Pharma (HELP) — surged 7.8% to $7.02 on bullish analyst coverage emphasizing the company's cash reserves and advancing psychedelic drug trials. The move snaps a five-session slide and raises a question every shareholder must answer: Is this stock a bargain backed by real science, or a speculative bet still years from proving it can make money?

• Nine Analysts Say "Strong Buy," but the Company Has Zero Revenue. According to 9 analysts, the average rating for HELP is "Strong Buy," with a 12-month price target of $37.96 — implying over 440% upside from the latest price.

Targets range from a low of $8 to a high of $70. That's an enormous spread, reflecting deep uncertainty. Cybin has a market capitalization of roughly $274 million and generates $0 in trailing revenue. In other words, the entire investment thesis rests on drugs that haven't been approved yet.

• A $248 Million Cash Cushion Buys Time — but Burns Fast. Cybin reported a net loss of $33.7 million in its fiscal Q2 2026 and a post-financing cash position of $248 million.

That provides roughly a 21–22 month runway, though ongoing equity raises signal high expected cash burn.

The company recently closed a $50 million underwritten offering to fund its second Phase 3 trial for depression.

Notably, the company carries no financial debt , a rarity for clinical-stage biotechs that limits dilution risk — for now.

• Phase 3 Data Later This Year Is the Real Catalyst. The main value driver is HLP003, the company's psilocybin-derived depression treatment, with Phase 3 results expected in Q4 2026.

Phase 2 data showed 100% response rates and 71% remission rates maintained at 12 months — exceptional numbers if they hold in larger trials. Its second drug, HLP004, targets generalized anxiety disorder and is in Phase 2.

• A White House Tailwind Adds Political Momentum. A White House executive order accelerating psychedelic research, clinical trials, and "Right to Try" access prompted Helus Pharma to welcome the regulatory boost , though the order does not change the legal status of these substances. It's a sentiment catalyst, not a regulatory shortcut.

The bottom line: today's pop rewards shareholders for patience, but the stock's fate hinges entirely on Q4 trial data. Until then, a $7 stock carrying a $38 consensus target is Wall Street's way of saying the science looks promising — if it works.